25,729 articles
HRS-4729
HRS-4729 (KAI-4729) is Hengrui's once-weekly injectable GLP-1/GIP/glucagon tri-agonist peptide for obesity, licensed to Kailera outside Greater China; its Phase 1 trial showed 16.0% weight loss at 12 weeks.
HRS-5346
HRS-5346 (MK-7262) is Hengrui's oral small-molecule lipoprotein(a) inhibitor, licensed to MSD outside Greater China for $200 million upfront; Phase 2 in China cut Lp(a) up to 86% at 12 weeks.
HRS-7249
HRS-7249: GalNAc-conjugated APOC3-targeting siRNA injection by Hengrui's Shanghai Tuojie unit, in phase 2 China trials for hyperlipidemia and severe hypertriglyceridemia; phase 1 TG cuts of 62-75%.
HRS-7535
HRS-7535 is Jiangsu Hengrui's once-daily oral small-molecule (nonpeptide) GLP-1 receptor agonist for type 2 diabetes and weight management; phase 2 trials showed HbA1c cuts up to 1.57% and weight loss up to 9.36%, with a China NDA accepted in 2026.
HRS-9821, PDE3/PDE4 dual inhibitor (COPD)
HRS-9821 (GSK-licensed Hengrui compound) is an investigational inhaled dual PDE3/PDE4 inhibitor for COPD add-on maintenance therapy, in phase II trials in China and licensed to GSK worldwide ex-Greater China in July 2025.
HRS9531 (瑞普泊肽)
HRS9531 (瑞普泊肽, ribupatide, KAI-9531) is Jiangsu Hengrui's once-weekly dual GLP-1/GIP receptor agonist for obesity and type 2 diabetes; phase 3 showed 19.2% weight loss at 48 weeks, with NDAs filed in China.
HS-10353
HS-10353 is Hansoh Pharmaceutical's investigational oral GABA-A receptor positive allosteric modulator, a zuranolone-like small molecule in Phase 2 trials for major depressive and postpartum depression, with Phase 1 efficacy and safety data published.
HS-10380
HS-10380 (Obuprazine, TRTL-107) is Hansoh Pharma's oral D2/D3 and 5-HT1A partial agonist, 5-HT2A antagonist antipsychotic for schizophrenia; Phase 2b showed PANSS gains versus placebo and aripiprazole, now in Phase 3.
HS-10535
HS-10535, also known as MK-4082, is an investigational oral small-molecule GLP-1 receptor agonist for obesity developed by China's Hansoh Pharma and globally licensed to Merck & Co. in December 2024.
HS-20094
HS-20094 (olatorepatide, 奥莱泊肽) is Hansoh Pharma's once-weekly dual biased GLP-1/GIP receptor agonist for diabetes and obesity, licensed to Regeneron outside Greater China; Phase 3 showed up to 19.3% weight loss at 48 weeks.
HS-20118 (AVR-001)
HS-20118 (AVR-001) is Hansoh Pharma's oral cyclic peptide interleukin-23 receptor antagonist for moderate-to-severe plaque psoriasis, licensed to Avere Therapeutics in 2026; Phase 1 data showed a 6-7 day half-life supporting once-weekly dosing and PASI 75 rates up to 75%.
HSD10 disease
HSD10 disease, also called HSD10 mitochondrial disease, is a rare X-linked neurometabolic disorder caused by HSD17B10 gene variants, fatal in most affected boys by early childhood.
HSK31858 (DPP1 inhibitor)
HSK31858, renamed florensocatib, is an oral non-covalent DPP1 (cathepsin C) inhibitor from Haisco, licensed to Chiesi outside greater China; SAVE-BE cut bronchiectasis exacerbations by 48-59%.
HSK39004
HSK39004 (AN01) is Haisco Pharmaceutical's inhaled dual PDE3/4 inhibitor for COPD maintenance, in dry powder and suspension forms, in Phase 3 in China and licensed to AirNexis for up to $1.063 billion.
HSK51155
HSK51155 is an oral, non-opioid analgesic candidate developed by China's Haisco Pharmaceutical, a selective Nav1.8 sodium channel inhibitor in phase 1 trials for migraine and licensed to AbbVie in 2026.
HSK55718
HSK55718 (HSK-55718) is Haisco Pharmaceutical's intravenous, small-molecule non-opioid NaV1.8 inhibitor analgesic for moderate-to-severe acute pain, in Phase II trials in China, with ex-Greater China rights licensed to AbbVie in April 2026.
HSK60002
HSK60002 is Haisco Pharmaceutical's class 1 oral small-molecule tablet, reported as a STAT6 PROTAC for inflammatory diseases. IND accepted July 2026, clinical approval August 2026 (atopic dermatitis, asthma), licensed to Sentivera for over $1.5 billion.
Huagai San
华盖散 (Huagai San, Canopy Powder) is a classical Chinese herbal formula from the Song dynasty Taiping Huimin Heji Jufang for wind-cold cough with phlegm; studied in cough variant asthma and chronic bronchitis and registered as granules in Macau and Taiwan.
Huaganjian
化肝煎 (Huaganjian), a seven-herb classic Chinese formula from Zhang Jingyue's Ming-era Jingyue Quanshu, vol. 51; treats liver depression transforming into fire with flank pain and bleeding; one of China's first 100 trial-exempt classic formulas.
Huanglian Gao
黄连膏 (Huanglian ointment, Coptis ointment): a traditional Chinese external oil ointment. The classical Qing Yizong Jinjian version, in the Ancient Classic Formulas catalogue, uses Coptis, Phellodendron, Rehmannia, Angelica tail, and turmeric in sesame oil and wax for sores; distinct from other same-named formulas.
Huangqi Guizhi Wuwu Decoction
黄芪桂枝五物汤 (Huangqi Guizhi Wuwu Decoction, HGWD), a five-herb classic formula from the Jingui Yaolue of Zhang Zhongjing, treats blood bi and is used for diabetic and chemotherapy-induced peripheral neuropathy.
Huangqi Tang
黄芪汤 (Huangqi decoction), a classical Chinese medicine formula from the Taiping Huimin Heji Jufang; variants contain astragalus with tangerine peel, hemp seed, and honey, or astragalus and licorice 6:1 (黄芪六一汤); studied in hepatitis B cirrhosis.
Huangqin Decoction
黄芩汤 (Huangqin Decoction): classical four-herb Chinese formula from Zhang Zhongjing's Shanghan Lun (scutellaria, peony, licorice, jujube) for heat-type diarrhea; second-batch classic formula, 2023.
Huashan Hospital
Huashan Hospital (华山医院), Fudan University, Shanghai; founded 1907 as the Chinese Red Cross General Hospital, first Chinese-run hospital in Shanghai; tertiary Grade A, 3,142 beds, national centers for neurological and infectious diseases.
Huashi Baidu granules
Huashi Baidu granules (化湿败毒颗粒) is a Chinese patent medicine developed in Wuhan during the COVID-19 pandemic and approved in China in March 2021 as one of the "three medicines and three formulations".
Hue
Hue: the color attribute ordering sensations around a color circle, independent of lightness and saturation. Rooted in cone-opponent retinal processing, formalized from Newton's color circle to CIECAM02 hue angle.
Hug machine
The hug machine, or squeeze machine, is a deep-pressure device invented by animal scientist Temple Grandin, who built the first one as a high school senior to calm her own anxiety.
Human anatomy
Human anatomy is the scientific study of the structures of the human body, studied historically by dissection and today by imaging such as CT and MRI.
Human antibodies
Human Antibodies (ISSN 1093-2607 print, 1875-869X online) is a quarterly peer-reviewed journal on human hybridomas and antibody technology, published by Sage since 2025 after IOS Press, indexed in Medline and Scopus.
Human anus
Human anus: external opening at the end of the gastrointestinal tract, terminating the 2.5-4 cm anal canal. Two sphincters, involuntary internal and voluntary external, maintain fecal continence; the pectinate line divides endoderm from ectoderm.